Should we target patients with autoimmune diseases for human papillomavirus vaccine uptake?

Expert Review of Vaccines

Volumn 13, Issue 8, 2014, Pages 931-934

  Feldman, Candace H ^a   Kim, Seoyoung C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Autoimmune disease; Cervical dysplasia; Human papillomavirus vaccine; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

WART VIRUS VACCINE;

AUTOIMMUNE DISEASE; AWARENESS; DRUG SAFETY; DRUG UTILIZATION; HEALTH EDUCATION; HUMAN; NONHUMAN; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINATION; ADOLESCENT; ATTITUDE TO HEALTH; COMPLICATION; FEMALE; PAPILLOMAVIRUS INFECTIONS; PATIENT ATTITUDE; UTILIZATION;

ADOLESCENT; AUTOIMMUNE DISEASES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; VACCINATION;

EID: 84904277998     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.930346     Document Type: Review

References (23)

1. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013(40): 187-93
2. Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106: 396-403
3. Kim SC, Glynn RJ, Giovannucci E, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis 2014. [Epub ahead of print]
4. Tam LS, Chan PK, Ho SC, et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus - a prospective cohort study. J Rheumatol 2010;37: 330-40
5. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103: 631-6
6. Rojo-Contreras W, Olivas-Flores EM, Gamez-Nava JI, et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus 2012;21: 365-72
7. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005;97: 577-86
8. Santana IU, Gomes Ado N, Lyrio LD, et al. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol 2011;30: 665-72
9. Heijstek MW, Scherpenisse M, Groot N, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis 2013. [Epub ahead of print]
10. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013;72: 659-64
11. Jacobson DL, Bousvaros A, Ashworth L, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis 2013;19: 1441-9
12. Gatto M, Agmon-Levin N, Soriano A, et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013;32: 1301-7
13. Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus 2012;21: 158-61
14. Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 2014;275: 398-408
15. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012;271: 193-203
16. Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013;347:f5906
17. Pellegrino P, Carnovale C, Pozzi M, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev 2014;13: 736-41
18. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. 2013. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6229a4. htm? s-cid=mm6229a4-e
19. Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc 2009;84: 864-70
20. Feldman CH, Hiraki LT, Lii J, Kim SC. Human Papillomavirus vaccine uptake among children and young adults with autoimmune diseases. Arthritis Rheum 2013;65:S361
21. Basu S, Chapman GB, Galvani AP. Integrating epidemiology, psychology, and economics to achieve HPV vaccination targets. Proc Natl Acad Sci USA 2008;105: 19018-23
22. Yazdany J, Tonner C, Trupin L, et al. Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study. Arthritis Res Ther 2010;12:R84
23. Morin MP, Quach C, Fortin E, Chedeville G. Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatology (Oxford) 2012;51: 2046-50